What if you could more accurately predict your patients risk of colorectal cancer?

The geneType for Colorectal Cancer risk score integrates broad genetic testing with traditional risk assessment modelling to provide a highly accurate personalised – and actionable – risk prediction.¹

Colorectal cancer is on the rise in adults under 50 years³

Screening guidelines have tried to address this issue by lowering the National FOBT screening recommendation age to 45.⁴

Patients are already stratified by family history, race/ethnicity and inflammatory bowel disease to assist with tailoring screening options.

Take risk stratification one step further by understanding your patient’s “baseline” risk with geneType.

*geneType is not a replacement for CRC screening; it is a risk assessment to help inform better screening and risk-reducing recommendations. This does not test for hereditary genetic syndromes associated with CRC.

Australia has the highest incident rates of colorectal cancer globally.⁵

^{How can you help your patient’s?}

• Identify your patient’s that need screening earlier than National population screening guidelines recommend.
• Let geneType help you manage compliance rates. Understand the risk of your non-compliant screeners.
• Identify your patient’s that would benefit from colonoscopies in addition to FOBT.

The geneType Patient

GeneType for Colorectal Cancer is appropriate for:

• Men and women
• Age 30 – 85 years

Exclusion criteria include a personal history of CRC, carrier of a known hereditary cancer syndrome (i.e. Lynch or FAP).

geneType does not test for hereditary cancer syndromes.